TY  - JOUR
AU  - Steingo, Brian
AU  - Al-Malik, Yaser
AU  - Bass, Ann D
AU  - Berkovich, Regina
AU  - Carraro, Matthew
AU  - Fernandez, Oscar
AU  - Ionete, Carolina
AU  - Massacesi, Luca
AU  - Meuth, Sven G
AU  - Mitsikostas, Dimos D
AU  - Pardo, Gabriel
AU  - Simm, Renata Faria
AU  - Traboulsee, Anthony
AU  - Choudhry, Zia
AU  - Daizadeh, Nadia
AU  - Compston, D Alastair S
PY  - 2020
DO  - 10.1007/s00415-020-09983-1
UR  - http://hdl.handle.net/10668/15820
T2  - Journal of neurology
AB  - In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing-remitting MS. Here, we assess efficacy and safety...
LA  - en
PB  - Springer
KW  - Alemtuzumab
KW  - Disease-modifying therapy
KW  - Efficacy
KW  - Long-term
KW  - Multiple sclerosis
KW  - Safety
KW  - Alemtuzumab
KW  - Antibodies, Monoclonal, Humanized
KW  - Follow-Up Studies
KW  - Humans
KW  - Interferon beta-1a
KW  - Multiple Sclerosis, Relapsing-Remitting
TI  - Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
TY  - research article
VL  - 267
ER  -